Axon: Raised Guidance And AI Momentum Can't Hide The Q3 Margin Trap At This Multiple — Hold

Axon Enterprise (NASDAQ: AXON) reported Q2 2026 revenue of $904 million, up 35% year over year, and beat consensus on both top line and non-GAAP earnings per share. Management raised full-year revenue guidance and pointed to nearly 700% growth in its AI Era Plan software offering. The stock fell 6.5% in after-hours trading on the news, then bounced back sharply over the next session. As of today, shares trade at $571, up 9.3% in the session and just $48 below the 52-week high of $844.

The operating story is still strong. The valuation is no longer the bargain it was at the 52-week low. And Q3 carries a specific margin headwind that management flagged plainly. I'm rating this Hold — the growth engine is intact but the multiple has run ahead of the near-term proof.

What changed in Q2

Revenue grew 35% to $904 million, the 10th consecutive quarter above 30% growth. Software & Services came in at $398 million (+36% YoY). Connected Devices hit $507 million (+35% YoY). Non-GAAP EPS of $1.88 beat the consensus estimate of $1.84. The guidance raise — from a 30-32% revenue growth range to 32-34% — signals management is confident the pipeline holds up through year-end.

Three bookings metrics tell the forward story: annual recurring revenue grew 39% to $1.6 billion, net revenue retention (the rate at which existing customers grow their spend, net of churn) sat at 126%, and future contracted bookings rose 41% to $15.1 billion. For a company selling into government procurement cycles, that booking momentum is not a one-quarter anomaly — it's a structural buildout.

The AI Era Plan grew nearly 700% year over year. That number is dramatic, but the base was small. What matters more is that newer software offerings — real-time operations tools, productivity apps, AI Era Plan, counter-drone software, Axon 911 — now make up over a third of software revenue and grew roughly 70% collectively. Axon is no longer just an evidence-management platform. It's building a broader public-safety operating system.

The earnings quality gap

Here's the friction point. GAAP net income for the quarter was $29 million, or $0.36 per diluted share. Non-GAAP net income was $155 million, or $1.88 per share. That gap — $126 million in non-GAAP adjustments — is driven largely by stock-based compensation, which management expects to run $590 million to $620 million for the full year. At this revenue scale, SBC is eating roughly 16% of top-line revenue. That's a structural cost of a high-growth tech compensation model, not a temporary charge, and it compresses the real cash economics beneath the adjusted headline.

Free cash flow tells its own story. The quarter posted a $1 million outflow — technically worse than breakeven. Operating cash flow turned positive at $20 million, up from a $92 million outflow a year ago, so the cash conversion direction is improving. But management is building inventory aggressively to mitigate supply chain risk and support demand. The full-year FCF guidance remains $450 million, which requires that inventory spending moderates in the second half. That's plausible but unproven.

The Q3 margin trap

This is the concrete reason the stock sold off in after-hours despite the beat. Q2's adjusted gross margin expanded 130 basis points sequentially to 62.9%, but that improvement was partly driven by a one-time tariff refund. Management was explicit: Q3 will not benefit from that refund and will face headwinds from rising memory component costs. The full-year adjusted EBITDA margin guidance remains at approximately 25.5%, which means Q4 has to absorb the Q3 drag and still close the year at target.

For a stock trading at 14.7x EV/sales and 356x EV/EBITDA, that Q3 pressure matters. The market has priced in a company whose margins expand smoothly. A sequential contraction, even a small one, is going to feel like a stumble at this multiple.

Valuation versus growth

The math doesn't hide well. At $571, Axon carries a trailing P/E of 233x and a forward P/E of 187x. The EV/EBITDA multiple sits at 356x. The price-to-sales ratio is 14.4x. The market cap is $46.4 billion on $3.24 billion in trailing revenue.

Compare that to Microsoft, which trades at 28x trailing earnings and 19x EV/EBITDA with an 11x sales multiple, or even Palantir at 137x earnings and 152x EV/EBITDA. Axon's growth rate of 35% is impressive, but it isn't enough to justify a multiple that sits between 10x and 20x the earnings multiple of the largest software names. The stock is pricing in years of flawless execution, uninterrupted margin expansion, and no geopolitical or procurement disruption.

The cheap-enough bridge — the idea that a valuation reset can absorb business risk and still leave upside — doesn't apply here. The stock isn't cheap. It's not even mid-range. It's at a premium multiple in the middle of its 52-week range, having recovered from $339 to $571 in roughly six months. The rally from the low created the valuation that now makes Q3 margin weakness a real concern rather than a temporary noise factor.

What would change the rating

The AI and counter-drone growth is real, not just narrative. International bookings tripled. Dedrone passed $100 million in quarterly revenue. The largest TASER order in company history was booked. Three of the top five AI Era Plan deals came from international customers. Axon is executing on product expansion and geographic diversification simultaneously.

But execution at this multiple requires margin proof, not just revenue proof. Two things would push me to upgrade to Buy:

• Q3 and Q4 deliver on the 25.5% adjusted EBITDA margin guidance despite the memory cost headwinds, and free cash flow reaccelerates toward the $450 million annual target. That would show the inventory build is temporary and the margin mix will normalize.
• The stock pulls back below $450, which would compress the forward multiple enough to give room for the near-term margin uncertainty.

Two things would push me to downgrade to Sell:

• Q3 adjusted EBITDA margin contracts materially below the path to the 25.5% full-year target, signaling the mix dilution from new products is worse than management expects.
• Bookings decelerate from the 40%+ growth rate, especially if international and enterprise segments lose momentum. At this multiple, slowing the growth engine is a multiple-compression event.

The holding call

Axon is a company with a durable growth story, real product differentiation, and a bookings pipeline that supports the raised guidance. The problem isn't the business — it's the stock's price relative to what still needs to be proven in the next two quarters.

Q3 is the test. The tariff refund tailwind disappears, memory costs rise, and the market will watch margins closely at a 233x trailing P/E. If Axon navigates that without a stumble and the Q4 close validates the EBITDA margin guidance, the growth story earns its premium. Until then, chasing a stock that already recovered from a 60% drawdown — with a known near-term margin headwind and a multiple that assumes perfection — is a risk/reward setup that doesn't favor new buyers.

Hold current positions. Wait for Q3 proof or a pullback that restores the cheap-enough bridge.

Next catalyst: Q3 2026 earnings release, expected late October or early November 2026. Watch adjusted EBITDA margin trajectory, free cash flow recovery, and whether bookings growth sustains the 40%+ pace.